| |
Newsroom /
Health and Fitness
/
Healthcare
/
Breast Cancer – Drug Pipeline Analysis and Market Forecasts to 2016
Breast Cancer – Drug Pipeline Analysis and Market Forecasts to 2016
The Breast Cancer Therapeutics Market is Forecast to Show High Growth Until 2016
Hyderabad,
AP,
India
(prbd.net)
27/01/2010
"Breast Cancer – Drug Pipeline Analysis and Market Forecasts to 2016"
GlobalData’s analysis suggests that the global breast cancer market was worth $8.7 billion in 2009. It is forecast to grow at a compound annual growth rate (CAGR) of 9.6% for the next seven years to reach $16.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline. Increases in the treatment seeking population, the diagnosis population and the availability new first-in-class therapies with better safety and efficacy are expected to drive the growth of the breast cancer market.
GlobalData analyzed the current competitive landscape for breast cancer drugs and found the competition to be strong. There are more than 30 marketed products for the treatment of breast cancer, which include chemotherapies, combinations and targeted therapies. Chemotherapy regimens, combination therapies and targeted therapies have adverse side-effects, sometimes fatal, despite their improved efficacy profiles. Also, evidence of resistance to HER2-targeted trastuzumab therapy in metastatic breast cancer patients and in early invasive phases of the disease has raised concerns, meaning that new targeted therapies are required. New entrants into the market will be forced to match or exceed the efficacy and safety profiles of the currently marketed products.
GlobalData analyzed the breast cancer pipeline and found it to be strong. The pipeline for breast cancer consists of more than 1,500 molecules currently in development for various disease segments. Approximately 15% of the breast cancer pipeline is accounted for by first-in-class molecules. In Phase III alone, there are 16 first-in-class molecules including vaccines, PARP inhibitors and mTOR inhibitors. These products are expected have better safety profiles than the current products. There are several combination therapies in development which incorporate recently introduced targeted therapies. A strong clinical pipeline coupled with high unmet needs in the breast cancer market is expected to help sustain the market’s high growth rate during the forecast period.
GlobalData has found that the global breast cancer market is a highly lucrative market with high levels of unmet need. The market has several hormonal therapies, chemotherapies, combinations and targeted therapies, which target patients with different disease characteristics. The efficacy profiles of these products have improved over the years, however, the safety profiles of these drugs are still unacceptable. Although the targeted therapies significantly improve efficacy in select patient segments, they are costlier and also have severe adverse effects. Therefore, the breast cancer market has high levels of unmet need that can be fulfilled by products that target underserved patient populations and offer improved safety and efficacy profiles.
GlobalData, the industry analysis specialist’s new report, “Breast Cancer – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global breast cancer market. The report identifies the key trends shaping and driving the global breast cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global breast cancer sector.
visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|